GO:1903561 extracellular vesicle: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903561 (extracellular vesicle) is defined as any vesicle that is part of the extracellular region, covering exosomes, microvesicles and apoptotic bodies released by cells.
• Extracellular vesicles (EVs) are lipid bilayer-delimited particles that carry proteins, nucleic acids and metabolites between cells and are now recognized as a major intercellular communication system.
• EV biogenesis proceeds through endosomal sorting complexes required for transport (ESCRT)-dependent and ESCRT-independent routes, followed by release and recipient-cell uptake.
• EVs interact with lipoproteins and other extracellular carriers, which affects their biodistribution and functional readouts.
• EVs are being developed as drug delivery vehicles, biomarkers and therapeutics in regenerative medicine and neurological disorders.
• Rigorous isolation, quality control and characterization (western blotting, tangential-flow filtration, particle analysis) are essential for reproducible EV research.
Description
Extracellular vesicles (EVs) are membrane-enclosed particles released by virtually all cell types into the extracellular space, and they are annotated in the Gene Ontology under GO:1903561 as any vesicle that is part of the extracellular region. This broad definition encompasses exosomes, microvesicles, ectosomes and apoptotic bodies, which differ in size, biogenesis route and molecular cargo but share the property of being delimited by a lipid bilayer and existing outside the plasma membrane. Because EVs carry proteins, lipids, RNAs and metabolites, they function as vehicles for intercellular communication and as potential biomarkers and therapeutic agents. For researchers, GO:1903561 provides a controlled vocabulary to describe the extracellular vesicle compartment in functional enrichment, proteomic and transcriptomic analyses. The term is widely used in studies of cancer, neurodegeneration, immune regulation and regenerative medicine, where EV cargo and uptake influence disease progression and treatment response. EVs also interact with lipoproteins and other extracellular particles, complicating isolation and interpretation of functional assays. Methodological advances in EV isolation, such as tangential-flow filtration and western blot-based characterization, have improved the reproducibility of EV research and enabled large-scale purification for translational applications. This article summarizes the ontology definition, biogenesis, molecular machinery, disease links and experimental strategies for studying GO:1903561, with emphasis on CRISPR-based models and quality-controlled workflows.
extracellular vesicle At A Glance
| GO ID | GO:1903561 |
|---|---|
| GO term | extracellular vesicle |
| Ontology | cellular_component |
| Synonym | microparticle |
| Definition | Any vesicle that is part of the extracellular region |
| Major function | Intercellular transport of proteins, nucleic acids and lipids; cell-cell communication |
| Related compartments | Endosome, multivesicular body, plasma membrane, extracellular region |
| Representative cargo | Tetraspanins (CD9, CD63, CD81), ESCRT proteins, heat shock proteins, miRNAs |
| Research relevance | Biomarkers, drug delivery, regenerative medicine, neurological disorders, cancer biology |
What Is GO:1903561?
GO:1903561 (extracellular vesicle) is a cellular component term describing any vesicle that is part of the extracellular region. In practice, this includes membrane-bound particles released from cells, such as exosomes, microvesicles and apoptotic bodies, which carry proteins, nucleic acids and lipids and can transfer cargo to recipient cells. The synonym microparticle is also used for some of these particles.
Why Is extracellular vesicle Important in Cell Biology?
GO:1903561 is important because extracellular vesicles mediate intercellular communication in physiology and disease, and they are actively developed as diagnostic biomarkers and therapeutic delivery systems. EVs can transfer proteins, RNAs and lipids between cells, influencing processes such as immune responses, tissue repair and tumor progression. Their presence in biofluids makes them attractive for liquid biopsy, while their biocompatibility and cargo capacity support drug delivery applications. However, EV heterogeneity and interactions with lipoproteins require careful isolation and quality control to ensure reproducible results.
• EVs are key mediators of intercellular communication, transferring proteins, RNAs and lipids between cells.
• EVs are promising biomarkers in cancer, neurological and cardiovascular diseases due to their presence in biofluids.
• EV-based therapeutics are being explored in regenerative medicine and neurological disorders.
• EVs can be engineered as drug delivery vehicles for small molecules, proteins and nucleic acids.
• EV isolation and characterization methods critically affect experimental reproducibility.
• EV-lipoprotein interactions influence EV biodistribution and functional assays.
• EV cargo reflects the physiological or pathological state of the parent cell, enabling non-invasive diagnostics.
• Quality control and nonclinical evaluation strategies are essential for translating EV products.
• EVs participate in immune regulation and inflammation, with implications for autoimmune and infectious diseases.
• CRISPR-based editing of EV-related genes enables causal dissection of biogenesis and cargo loading.
Molecular and Cellular Basis of GO:1903561 (extracellular vesicle)
Biogenesis and Release of Extracellular Vesicles
In simple terms: Cells package cargo into small membrane bubbles and release them outside.
Extracellular vesicle biogenesis begins with cargo sorting at the plasma membrane or in endosomal compartments, followed by membrane budding and release. Exosomes originate from multivesicular bodies (MVBs) through inward budding of the endosomal membrane, while microvesicles bud directly from the plasma membrane. The endosomal sorting complexes required for transport (ESCRT) machinery, including TSG101 and VPS4, mediate one major route of exosome formation, whereas ESCRT-independent pathways involving tetraspanins and ceramide also contribute. Once released, EVs can travel in extracellular fluids and interact with recipient cells via receptor-ligand binding, fusion or endocytosis.
Cargo Sorting and Molecular Composition
In simple terms: The bubble carries a specific set of proteins and RNAs determined by sorting signals.
EV cargo includes tetraspanins (CD9, CD63, CD81), ESCRT components, heat shock proteins, cytoskeletal proteins, lipids and nucleic acids such as mRNA and miRNA. Sorting of cargo into EVs is regulated by post-translational modifications, lipid microdomains and interactions with sorting machinery. Proteomic and transcriptomic profiling has revealed that EV cargo is not a random sample of the cell but is enriched for specific molecules, which underpins their functional roles. Western blotting for tetraspanins and other markers is a standard method for EV characterization.
Interaction with Lipoproteins and Extracellular Environment
In simple terms: EVs can stick to or exchange material with lipoprotein particles in the blood.
EVs coexist with lipoproteins in biofluids and can interact with them, affecting EV isolation, quantification and functional interpretation. These interactions may alter EV biodistribution and uptake by recipient cells, and they complicate the assignment of biological effects to EVs versus lipoproteins. Researchers must therefore use appropriate separation methods and controls when studying EV functions in complex biological fluids.
Uptake and Functional Delivery to Recipient Cells
In simple terms: Target cells take in the bubble and use its cargo to change their behavior.
Recipient cells internalize EVs through multiple mechanisms, including clathrin-mediated endocytosis, macropinocytosis, phagocytosis and direct membrane fusion. After uptake, EV cargo can modulate signaling pathways, gene expression and cellular phenotypes in the recipient cell. This transfer of functional molecules underlies EV roles in immune modulation, tissue repair and tumor progression. Understanding uptake mechanisms is critical for engineering EVs as targeted delivery vehicles.
Isolation and Quality Control of Extracellular Vesicles
In simple terms: Scientists use special methods to separate EVs from other particles and check their purity.
EV isolation methods include differential ultracentrifugation, size-exclusion chromatography, tangential-flow filtration and immunoaffinity capture. Tangential-flow filtration enables large-scale purification of EVs with defined size characteristics. Quality control involves particle size and concentration analysis, electron microscopy, western blotting for EV markers and assessment of non-EV contaminants. Standardized isolation and characterization are essential for comparing results across studies and for developing EV-based therapeutics.
Key Genes Involved in GO:1903561 extracellular vesicle
The following genes and proteins are central to extracellular vesicle biogenesis, cargo sorting, release and uptake, and they are frequently studied using CRISPR-based approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD9 | Tetraspanin enriched on EV membranes; involved in cargo sorting and uptake | EV marker; KO reduces EV release and alters cargo |
| CD63 | Tetraspanin marker of exosomes and multivesicular bodies | EV characterization marker; KO affects exosome composition |
| CD81 | Tetraspanin involved in EV-mediated cell adhesion and signaling | EV marker; functional studies in immune and cancer cells |
| TSG101 | ESCRT-I component required for exosome biogenesis | KO inhibits exosome formation; used to dissect ESCRT-dependent pathways |
| VPS4A | AAA-ATPase that drives ESCRT disassembly and MVB sorting | Dominant-negative or KO blocks EV release |
| VPS4B | Paralog of VPS4A involved in ESCRT-mediated membrane remodeling | KO studies reveal redundancy in EV biogenesis |
| ALIX (PDCD6IP) | Accessory ESCRT protein involved in exosome budding | KO alters exosome cargo and release |
| RAB27A | Small GTPase regulating MVB docking and exosome secretion | KO reduces exosome release; studied in cancer and immune cells |
| RAB27B | GTPase involved in secretory vesicle trafficking and EV release | KO affects EV secretion in specific cell types |
| RAB11A | GTPase regulating recycling endosome and EV cargo transport | KO impacts EV composition and release |
| SMPD3 | Neutral sphingomyelinase generating ceramide for ESCRT-independent EV budding | KO reduces ceramide-dependent EV formation |
| nSMase2 (SMPD3) | Enzyme producing ceramide implicated in EV biogenesis | Inhibitor and KO studies link ceramide to EV release |
| HSPA8 | Heat shock cognate protein involved in protein sorting into EVs | KO or knockdown alters EV proteome |
| HSP90AA1 | Chaperone contributing to EV cargo selection | Inhibition affects EV protein content |
| ACTB | Cytoskeletal protein influencing EV budding and cargo | KO affects membrane dynamics and EV release |
| SDC1 (Syndecan-1) | Proteoglycan involved in EV uptake and cargo delivery | KO reduces EV internalization in recipient cells |
| ITGB1 | Integrin mediating EV adhesion and uptake | KO alters EV targeting to specific cell types |
| ICAM1 | Adhesion molecule facilitating EV docking on recipient cells | KO affects EV-mediated immune signaling |
How Is extracellular vesicle Regulated?
Extracellular vesicle biogenesis and release are regulated at multiple levels, including ESCRT-dependent and ESCRT-independent pathways, small GTPases such as RAB27A and RAB11A, lipid metabolism enzymes like SMPD3, and cytoskeletal dynamics. Cellular stress, calcium signaling and changes in membrane lipid composition can modulate EV secretion. In addition, EV cargo sorting is influenced by post-translational modifications and interactions with chaperones such as HSPA8 and HSP90AA1. The extracellular environment, including lipoprotein interactions, can further affect EV stability and function.
extracellular vesicle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RAB27A | Cancer progression and EV-mediated metastasis | KO in cancer cell lines; EV release and invasion assays |
| TSG101 | Tumor-derived exosome biogenesis | KO in tumor cells; exosome quantification and cargo analysis |
| CD63 | Neurodegenerative disease EV biomarkers | Knock-in of tagged CD63 in neuronal cells; EV tracking |
| SMPD3 | Ceramide-dependent EV release in inflammation | KO in macrophages; EV release and cytokine assays |
| ITGB1 | EV uptake in cancer and immune cells | KO in recipient cells; EV internalization assays |
Extracellular Vesicles in Cancer
EVs are released in large numbers by tumor cells and can transfer oncogenic proteins, mRNAs and miRNAs to recipient cells, promoting proliferation, angiogenesis, immune evasion and metastasis. EV cargo profiles in biofluids are being explored as cancer biomarkers, and EV-mediated drug resistance has been documented. Targeting EV biogenesis genes such as RAB27A or TSG101 with CRISPR can reduce EV release and may limit tumor progression in experimental models.
Extracellular Vesicles in Neurological Disorders
EVs participate in neuron-glia communication and can spread pathological proteins such as amyloid-beta and alpha-synuclein in neurodegenerative diseases. EV-based therapies are being investigated for delivering neuroprotective cargo across the blood-brain barrier. CRISPR screens in neuronal cells can identify genes that regulate EV-mediated protein spread and neurotoxicity.
Extracellular Vesicles in Regenerative Medicine
Mesenchymal stem cell-derived EVs carry regenerative cargo that can promote tissue repair and modulate inflammation. EV therapeutics are being developed for wound healing, cardiovascular repair and immune modulation. Genetic engineering of EV-producing cells using CRISPR can enhance therapeutic cargo loading and targeting.
Extracellular Vesicles and Lipoprotein Interactions in Disease
EV-lipoprotein interactions can influence the biodistribution of EV-associated cargo and may contribute to cardiovascular and metabolic disease pathology. These interactions complicate the interpretation of EV biomarker studies and require careful experimental design. CRISPR-based models can help distinguish EV-specific effects from lipoprotein-associated effects.
From extracellular vesicle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TSG101 reduce exosome release? | CRISPR knockout of TSG101 in HEK293 or cancer cells |
| How does a point mutation in RAB27A affect EV secretion? | CRISPR point mutation knock-in of RAB27A in donor cells |
| Can tagged CD63 be used to track EV uptake? | Knock-in of fluorescent protein tag at CD63 locus |
| Does overexpression of ALIX increase EV cargo loading? | CRISPR overexpression or cDNA overexpression of ALIX |
| Which genes regulate EV-mediated transfer of oncogenic cargo? | Genome-wide CRISPR knockout library screening in EV donor cells |
| Does KO of ITGB1 in recipient cells block EV uptake? | CRISPR knockout of ITGB1 in recipient cells followed by EV uptake assay |
How to Study the extracellular vesicle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Differential ultracentrifugation | EV enrichment based on density and size | Standard EV isolation from conditioned media |
| Tangential-flow filtration | Large-scale EV purification with size cutoff | Bioreactor-scale EV production |
| Western blotting | Presence of EV markers and absence of contaminants | EV identity and purity assessment |
| Nanoparticle tracking analysis | Particle size distribution and concentration | EV characterization and quality control |
| Flow cytometry | EV uptake by recipient cells | Functional EV internalization assays |
| Proteomics | Protein cargo composition of EVs | Biomarker discovery and sorting studies |
| Small RNA sequencing | miRNA and other small RNA cargo | EV-mediated gene regulation studies |
| CRISPR knockout screening | Genes regulating EV biogenesis or uptake | Functional genomics of EV pathways |
EV Isolation and Purification
Differential ultracentrifugation, size-exclusion chromatography, tangential-flow filtration and immunoaffinity capture are standard methods for isolating EVs from conditioned media or biofluids. Tangential-flow filtration supports large-scale purification with reproducible size profiles. The choice of method affects EV yield, purity and downstream functional assays.
EV Characterization by Western Blotting and Particle Analysis
Western blotting for tetraspanins (CD9, CD63, CD81) and negative markers (e.g., calnexin) is used to confirm EV identity and purity. Nanoparticle tracking analysis, dynamic light scattering and electron microscopy provide size and concentration information. These orthogonal methods are recommended for rigorous EV characterization.
Functional Assays for EV Uptake and Cargo Transfer
Fluorescently labeled EVs can be used to measure uptake by recipient cells via flow cytometry or imaging. Cargo transfer can be assessed by detecting EV-derived RNA or protein in recipient cells. CRISPR knockout of candidate uptake genes in recipient cells helps establish causal roles.
Omics Profiling of EV Cargo
Proteomics, transcriptomics and small RNA sequencing of isolated EVs reveal cargo composition and candidate biomarkers. Comparative omics of donor cells and their EVs identifies sorting determinants. Bioinformatics integration with GO:1903561 annotation supports functional interpretation.
How CRISPR Can Be Used to Study GO:1903561 extracellular vesicle
Knockout
CRISPR knockout of EV-related genes such as TSG101, RAB27A or CD63 is used to test their requirement for EV biogenesis, release and cargo sorting. Knockout cell lines can be compared with wild-type controls in EV quantification and functional transfer assays. This approach provides causal evidence for gene function in the EV pathway.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants in EV genes or disrupt specific functional domains, such as GTPase activity of RAB27A. These models help dissect domain-specific functions without altering protein expression levels. Point mutations can also be used to study post-translational modification sites involved in cargo sorting.
Knock-in
Knock-in of fluorescent or affinity tags at endogenous loci (e.g., CD63-GFP) enables real-time tracking of EV biogenesis and uptake. Tagged knock-in models preserve physiological regulation of the target gene. These tools are valuable for imaging EV trafficking in live cells.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression of EV cargo proteins or biogenesis factors can enhance EV production or modify cargo composition. Overexpression models are used to test sufficiency of a gene in EV release and to engineer EVs for therapeutic delivery. Controlled overexpression systems help avoid artifacts from supraphysiological expression.
How EDITGENE Supports extracellular vesicle Research
Researchers studying extracellular vesicle-related genes often need to determine whether a candidate gene is causally involved in EV biogenesis, cargo sorting or uptake, and CRISPR-based models provide a precise way to test these hypotheses. By combining knockout, point mutation, knock-in and overexpression strategies with rigorous EV isolation and characterization, it is possible to build reproducible and publication-ready datasets.
Contact EDITGENE today to design your custom CRISPR model for extracellular vesicle research.
Frequently Asked Questions About extracellular vesicle
What is GO:1903561?
GO:1903561 is the Gene Ontology term for extracellular vesicle, defined as any vesicle that is part of the extracellular region, including exosomes, microvesicles and apoptotic bodies.
What is an extracellular vesicle?
An extracellular vesicle is a membrane-bound particle released by cells into the extracellular space that carries proteins, lipids and nucleic acids and can transfer them to recipient cells.
What genes are involved in extracellular vesicle biogenesis?
Key genes include TSG101, VPS4A, VPS4B, ALIX, RAB27A, RAB27B, RAB11A, SMPD3, CD9, CD63 and CD81, which regulate EV formation, cargo sorting and release.
How are extracellular vesicles isolated?
Common isolation methods include differential ultracentrifugation, size-exclusion chromatography, tangential-flow filtration and immunoaffinity capture, often followed by western blotting and particle analysis for quality control.
What is the difference between exosomes and microvesicles?
Exosomes originate from multivesicular bodies via inward budding, while microvesicles bud directly from the plasma membrane; both are subtypes of extracellular vesicles under GO:1903561.
Why are extracellular vesicles important in cancer?
Tumor-derived EVs can transfer oncogenic cargo to recipient cells, promote metastasis and immune evasion, and serve as biomarkers for cancer detection.
Can extracellular vesicles be used for drug delivery?
Yes, EVs are being developed as drug delivery vehicles because of their biocompatibility and ability to carry diverse cargo, although quality control and manufacturing challenges remain.
How do CRISPR screens help study extracellular vesicles?
CRISPR knockout screens can identify genes that regulate EV biogenesis, cargo sorting and uptake, providing causal insights into EV biology.
What markers are used to identify extracellular vesicles?
Tetraspanins such as CD9, CD63 and CD81 are commonly used EV markers, along with ESCRT proteins and heat shock proteins.
What diseases are linked to extracellular vesicles?
EVs are implicated in cancer, neurological disorders, cardiovascular disease and regenerative medicine applications.
Conclusion
GO:1903561 (extracellular vesicle) defines a diverse and biologically important compartment that mediates intercellular communication and holds promise for diagnostics and therapeutics. Understanding EV biogenesis, cargo sorting and uptake requires rigorous methods and causal genetic models. CRISPR-based knockout, knock-in, point mutation and overexpression approaches, combined with quality-controlled EV isolation and omics profiling, provide a robust framework for dissecting EV biology and translating findings to disease.
References
- 1. Xu G et al.. 2025. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies.. Signal Transduct Target Ther 10(1):255 PMID: 40804047
- 2. Kowal EJK et al.. 2017. Extracellular Vesicle Isolation and Analysis by Western Blotting.. Methods Mol Biol 1660:143-152 PMID: 28828654
- 3. Ghebosu RE et al.. 2024. Extracellular Vesicle and Lipoprotein Interactions.. Nano Lett 24(1):1-8 PMID: 38122812
- 4. Ma Y et al.. 2023. Extracellular vesicle-embedded materials.. J Control Release 361:280-296 PMID: 37536545
- 5. van Niel G et al.. 2018. Shedding light on the cell biology of extracellular vesicles.. Nat Rev Mol Cell Biol 19(4):213-228 PMID: 29339798
- 6. Putthanbut N et al.. 2024. Extracellular vesicle therapy in neurological disorders.. J Biomed Sci 31(1):85 PMID: 39183263
- 7. Yuan R et al.. 2023. Extracellular Vesicle Isolation by a Tangential-Flow Filtration-Based Large-Scale Purification Method.. Methods Mol Biol 2668:45-55 PMID: 37140789
- 8. Imafuku A et al.. 2021. Extracellular Vesicle Therapeutics in Regenerative Medicine.. Adv Exp Med Biol 1312:131-138 PMID: 33330962
